| Full text | |
| Author(s): |
Vitorino, Hector Aguilar
[1]
;
Mantovanelli, Luca
[2]
;
Zanotto, Flavia Pinheiro
[2]
;
Esposito, Breno Pannia
[1]
Total Authors: 4
|
| Affiliation: | [1] Univ Sao Paulo, Inst Quim, Sao Paulo - Brazil
[2] Univ Sao Paulo, Inst Biociencias, Sao Paulo - Brazil
Total Affiliations: 2
|
| Document type: | Journal article |
| Source: | PLoS One; v. 10, n. 4 APR 7 2015. |
| Web of Science Citations: | 11 |
| Abstract | |
Iron metallodrugs comprise mineral supplements, anti-hypertensive agents and, more recently, magnetic nanomaterials, with both therapeutic and diagnostic roles. As biologically-active metal compounds, concern has been raised regarding the impact of these compounds when emitted to the environment and associated ecotoxicological effects for the fauna. In this work we assessed the relative stability of several iron compounds (supplements based on glucoheptonate, dextran or glycinate, as well as 3,5,5-trimethylhexanoyl (TMH) derivatives of ferrocene) against high affinity models of biological binding, calcein and aprotransferrin, via a fluorimetric method. Also, the redox-activity of each compound was determined in a physiologically relevant medium. Toxicity toward Artemia salina at different developmental stages was measured, as well as the amount of lipid peroxidation. Our results show that polymer-coated iron metallodrugs are stable, non-redox-active and non-toxic at the concentrations studied (up to 300 mu M). However, TMH derivatives of ferrocene were less stable and more redox-active than the parent compound, and TMH-ferrocene displayed toxicity and lipid peroxidation to A. salina, unlike the other compounds. Our results indicate that iron metallodrugs based on polymer coating do not present direct toxicity at low levels of emission; however other iron species (eg. metallocenes), may be deleterious for aquatic organisms. We suggest that ecotoxicity depends more on metal speciation than on the total amount of metal present in the metallodrugs. Future studies with discarded metallodrugs should consider the chemical speciation of the metal present in the composition of the drug. (AU) | |
| FAPESP's process: | 11/50318-1 - Development of compounds with pharmacological or medicinal interest and of systems for their transport, detection and recognition in biological media |
| Grantee: | Ana Maria da Costa Ferreira |
| Support Opportunities: | Research Projects - Thematic Grants |